<DOC>
	<DOC>NCT02229253</DOC>
	<brief_summary>Patients with prostate cancer and a history of cardiovascular disease treated with degarelix for their prostate cancer, will be followed for a period of one year. In this real-life, non-interventional trial, any cardiovascular events occurring during degarelix therapy will be documented.</brief_summary>
	<brief_title>Real-life Data of Cardiovascular Events Occuring During Degarelix Therapy for Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Patients with prostate cancer and a history of cardiovascular disease, prescribed degarelix for the treatment of their prostate cancer Patients who have received a form of androgen deprivation therapy for their prostate cancer, during the 12 months preceding this study are excluded Planned intermittent or shortterm (&lt; 12 months) degarelix treatment Planned addition of, or switch to another form of androgen deprivation therapy during the study</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>